Edgewise Therapeutics, Inc. Share Price & Technical Analysis
EWTX · $32.27 (-1.68%)
Healthcare / Biotechnology
$32.27
-1.68%
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
5% return in May, -2% avg return in past 3 year May month.
27% return in 2026, 60% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 12% | 8% | 5% | -3% | 5% | – | – | – | – | – | – | – | 27% |
| 25 | 4% | -6% | -15% | -25% | -13% | -9% | 9% | 2% | 12% | 14% | 42% | -5% | 10% |
| 24 | 63% | -9% | 12% | -2% | -5% | 3% | -6% | 10% | 42% | 24% | -2% | -19% | 111% |
| 23 | 13% | -6% | -31% | 31% | 11% | -23% | -4% | -14% | -10% | 12% | -5% | 82% | 58% |
| 22 | -7% | -14% | -18% | -18% | -22% | 29% | 21% | 6% | -3% | -4% | -7% | -1% | -37% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.65B
P/E ratio
—
52W high
$39.96
52W low
$12.15
Volume
24,353
Beta
0.25
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Edgewise Therapeutics, Inc. share price today?
- Edgewise Therapeutics, Inc. (EWTX) last traded around $32.27 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does EWTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for EWTX. Download the app for real-time alerts.
- How can I analyze Edgewise Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.